Compare BCG & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCG | PLUR |
|---|---|---|
| Founded | 2016 | 2001 |
| Country | United States | Israel |
| Employees | 150 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.4M | 25.5M |
| IPO Year | N/A | 2001 |
| Metric | BCG | PLUR |
|---|---|---|
| Price | $1.36 | $1.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 15.8K | ★ 43.7K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,336,000.00 |
| Revenue This Year | N/A | $97.38 |
| Revenue Next Year | N/A | $293.97 |
| P/E Ratio | $56.15 | ★ N/A |
| Revenue Growth | N/A | ★ 309.82 |
| 52 Week Low | $1.36 | $1.56 |
| 52 Week High | $3.44 | $5.68 |
| Indicator | BCG | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 31.51 | 38.86 |
| Support Level | $1.36 | $1.56 |
| Resistance Level | $1.61 | $2.50 |
| Average True Range (ATR) | 0.07 | 0.18 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 0.00 | 31.61 |
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.